ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Clinical trials for ER-POSITIVE HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER-POSITIVE HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER-POSITIVE HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo could delay cancer worsening in breast cancer patients
Disease control OngoingThis study looks at whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor is better than staying on standard hormone therapy (letrozole or anastrozole) plus a CDK4/6 inhibitor for people with advanced HR+/HER2- breast cancer that has a specific gene change (ESR1 …
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 01, 2026 15:56 UTC
-
New hope for advanced breast cancer: could camizestrant outperform standard care?
Disease control OngoingThis study compares a new oral drug, camizestrant, combined with palbociclib, against the standard treatment (anastrozole plus palbociclib) for people with ER-positive, HER2-negative advanced breast cancer who haven't had prior treatment for advanced disease. About 1370 participa…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
AI predicts breast cancer recurrence risk in new study
Knowledge-focused OngoingThis study looks at whether an artificial intelligence (AI) program can accurately predict if early-stage breast cancer will come back. Researchers will analyze tumor samples and health records from 2,200 past patients. The goal is to see if the AI can help doctors decide which p…
Matched conditions: ER-POSITIVE HER2-NEGATIVE BREAST CANCER
Sponsor: Spotlight Medical • Aim: Knowledge-focused
Last updated Apr 29, 2026 15:02 UTC